IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

• Egile Nagusiak: Stephanie L. Gu (Egilea), Tara Maier (Egilea), Andrea P. Moy (Egilea), Stephen Dusza (Egilea), David M. Faleck (Egilea), Neil J. Shah (Egilea), Mario E. Lacouture (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2023-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

<b>Background</b>: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype. We report the use of ustekinumab as a thera...